BIO PRODUCTS LABORATORY (BPL) acquired by PERMIRA
Context
Permira acquired BPL from its sole shareholder, Tiancheng International Investment (TII), which had owned the business since 2016. The acquisition was part of a larger strategic plan to merge BPL's robust US collection network and specialized rare disease portfolio with Kedrion. By detaching BPL from its Chinese parent company, Permira allowed the business to refocus on its core UK and US markets. The combination created massive synergies in fractionation capacity and plasma supply, solving long-standing raw material bottlenecks for the UK-based manufacturing facilities.
BIO PRODUCTS LABORATORY (BPL), which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
BPL is a pioneer in the plasma industry, primarily focused on the development and manufacture of rare disease therapies. It operates two divisions: BPL Plasma (operating ~29 collection centers in the US) and BPL Therapeutics (manufacturing in the UK). Its products treat immune deficiencies, bleeding disorders, and infectious diseases.
Ent. Value
£250–500M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (GBP)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2022 | FRESENIUS | MABXIENCE | SPAIN | CDMO |
| 02/2022 | MONTAGU PRIVATE EQUITY / PARTNERS GROUP | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 01/2022 | PERMIRA | KEDRION | ITALY | CDMO |
| 01/2022 | ANJAC BEAUTY & HEALTH | APOLLO HEALTHCARE CORP. | CANADA | CDMO |
| 01/2022 | ARDIAN | BIOFARMA GROUP | ITALY | CDMO |
| 12/2021 | THE CARLYLE GROUP / GTCR | RESONETICS | UNITED STATES | Medical Devices |
| 12/2021 | INTEGER | OSCOR | UNITED STATES | Implants & Prosthetics |
| 12/2021 | WINNCARE | PHARMAOUEST INDUSTRIES | FRANCE | Medical Devices |
| 12/2021 | PLANMECA GROUP | KAVO DENTAL | GERMANY | Medical Devices |
| 11/2021 | COLOPLAST | ATOS MEDICAL | SWEDEN | Medical Consumables |
Other operations with PERMIRA
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | PERMIRA / WARBURG PINCUS | CLEARWATER ANALYTICS | UNITED STATES | Financial Services / Banking |
| 01/2026 | PERMIRA | CARNE GROUP | IRELAND | Healthcare Services |
| 11/2025 | PERMIRA | JTC | UNITED KINGDOM | Wealth & Asset Management |
| 10/2024 | PERMIRA | SQUARESPACE | UNITED STATES | Software |
| 10/2024 | PERMIRA | K-WAY | FRANCE | Fashion & Apparel |
| 09/2024 | PERMIRA | HOTEL ENGINE | UNITED STATES | Travel / Hospitality |
| 06/2024 | PERMIRA | PHARMACORD | UNITED STATES | Health Tech |
| 12/2023 | PERMIRA | GGW GROUP | GERMANY | Brokerage |
| 09/2023 | PERMIRA | ERGOMED | UNITED KINGDOM | CRO / Clinical Trials |
| 05/2023 | PERMIRA | GRUPPO FLORENCE | ITALY | Fashion & Leather Goods |
REFERENCES
Revenue range: £250–500M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of BIO PRODUCTS LABORATORY (BPL) by PERMIRA are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: permira